Business · National
Natco Pharma gets USFDA’s EIR for Visakhapatnam plant
August inspection drew four Form-483 observations; regulator classifies as Voluntary Action Indicated
Verified Timeline
No verified timeline updates.
What is your view on “Natco Pharma gets USFDA’s EIR for Visakhapatnam plant”?
This is self-selected reader participation, not representative scientific polling.

